Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar

A biosimilar product needs to demonstrate biosimilarity to the originator reference product, and the quality profile of the latter should be monitored throughout the period of the biosimilar's development to match the quality attributes of the 2 products that relate to efficacy and safety. For...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:MAbs
Päätekijät: Kim, Seokkyun, Song, Jinsu, Park, Seungkyu, Ham, Sunyoung, Paek, Kyungyeol, Kang, Minjung, Chae, Yunjung, Seo, Heewon, Kim, Hyung-Chan, Flores, Michael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2017
Aiheet:
Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5419076/
https://ncbi.nlm.nih.gov/pubmed/28296619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2017.1305530
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia